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Abstract 
The Pediatric Eye Disease Investigator Group reported the prevalence of amblyopia to be between 1% and 
4% making amblyopia the most common visual impairment in children. The classic and simple method of 
patching the non-amblyopic eye has been a mainstay of initial amblyopia treatment for most eye 
practitioners. This penalizes the sound eye and requires the amblyopic eye to be used. However, in the 
first phase of the Amblyopia Treatment Study researchers found that there was no significant difference 
in effectiveness between patch and atropine therapy over a six month therapy period. ATS 1 proved equal 
effectivity showing that the six-month acuity had improved from baseline by 3 or more lines in 79% of the 
subjects in the patched group and 74% for the atropine group. While each method of treatment has 
advantages and disadvantages for use, we find that atropine offers a mode of treatment with improved 
cosmesis, ease of administration and a potential for increased compliance with children who are 
resistant to traditional amblyopia treatment. 
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Abstract: 
The Pediatric Eye Disease Investigator Group reported the prevalence of amblyopia to be 
between 1% and 4% making amblyopia the most common visual impairment in children. The 
classic and simple method of patching the non-amblyopic eye has been a mainstay of initial 
amblyopia treatment for most eye practitioners. This penalizes the sound eye and requires the 
amblyopic eye to be used. However, in the first phase of the Amblyopia Treatment Study 
researchers found that there was no significant difference in effectiveness between patch and 
atropine therapy over a six month therapy period. ATS 1 proved equal effectivity showing that 
the six-month acuity had improved from baseline by 3 or more lines in 79% of the subjects in the 
patched group and 74% for the atropine group. While each method of treatment has advantages 
and disadvantages for use, we find that atropine offers a mode of treatment with improved 
cosmesis, ease of administration and a potential for increased compliance with children who are 
resistant to traditional amblyopia treatment. 
Key Words: amblyopia, Amblyopia Treatment Study, anisometropia, atropine, children, 
compliance, congenital cataracts, cosmesis, deprivation amblyopia, high refractive error, neural 
inhibition/stimulation, occlusion therapy, optical penalization, patching, PEDIG, stereopsis, 
strabismus, vision loss, visual acuity, visuoscopy. 
Acknowf edge~nents: 
We would Ii ke to first thank each of our family members fur giving us 
the support necessary to complete our doctorate in optometry. We would 
also like to thank Dr. London for his insight and teaching along the way. 
Introduction 
One of the great challenges facing eye care practitioners when providing care for 
pediatric patients is the treatment and management of amblyopia. The visual system of 
young children is actively evolving and is sensitive to disruption. When this disruption 
occurs during a sensitive developmental period the brain undergoes adaptation to 
compensate. This commonly involves the active suppression of the disadvantaged eye, 
which is termed amblyopia. The major causes of amblyopia are strabismus, 
anisometropia, high refractive error, deprivation amblyopia caused for example by 
congenital cataracts or ptosis, or a combination of the above. In order to improve the 
visual acuity of the amblyopic eye, the amblyogenic stimulus must first be removed and 
second, the amblyopic eye must be given an advantage over the dominant eye. 
While treatment typically consists of a simple patching regimen, amblyopia is still 
the leading cause of preventable vision loss in children and young adults under age 45. 
The prevalence of ambylopia is estimated at 2-2.5 % in the general population, which 
translates to approximately 7,500,000 cases in the U.S.' Although amblyopia is primarily 
defined by a level of reduced visual acuity, it has a negative impact on accommodative, 
binocular, and oculomotor functions as well2. This unilateral vision loss ultimately leads 
to decreased stereopsis, which can affect eye hand performance and overall coordination. 
Another major concern for children with amblyopia is the fact that there is a higher risk 
of injury to the sound eye than in children with two normally functioning eyes.3 It is 
therefore imperative that eye care physicians fully understand the latest research and 
treatment paradigms regarding effective management of patients with amblyopia. 
Proper Assessment of Amblyopia 
Before deciding to initiate on a treatment plan for amblyopia, it is vitally 
important to properly assess the patient's visual status. Since a diagnosis of amblyopia is 
one of exclusion, a proper amblyopia work up not only involves testing of refractive error 
and visual acuity, but also includes a precise measurement of strabismus, visuoscopy, and 
a full assessment of ocular health. Once amblyopia is diagnosed, the correct type of 
amblyopia must be determined because the treatment differs. 
Strabismic amblyopia occurs due to a constant strabismus with an onset before the 
patient is 6 years of age. Intermittent and alternating strabismic deviations, without other 
complications, do not cause amblyopia.4 Diplopia and/or visual confusion associated with 
a deviation of the visual axis in the strabismic eye lead to suppression of the deviated eye. 
This inhibition then results in cortical spatial changes and decreased visual acuity.5 
Anisometropic amblyopia, due to unequal refractive error, causes an inhibition of 
one eye due to unequal image clarity. Isometropic amblyopia is due to high bilateral 
uncorrected refractive error and causes a bilateral reduction in acuity levels. 
Deprivational amblyopia is the most serious of amblyopia causes. This occurs when 
there is a physical obstruction of the line of sight such as ptosis, corneal opacities, or 
congenital cataracts. These patients have a much worse prognosis for improvement due 
the fact that most of these retinal cells have been unable to receive any neural stimulation. 
No matter the cause of the amblyopia, poor visual function found in the 
amblyopic eye is due to direct neural inhibition. In a single unit recording analysis of the 
striate cortex neurons of macaque monkeys, both anisometropic and strabismic 
amblyopes had a reduced response to high spatial frequency signals in the amblyopic eye. 
The investigators learned that the high spatial frequency neurons of the bctter sighted eye 
suppress the response from the amblyopic n c u r ~ n s . ~  This srippression which results From 
unequal inputs was significantly decreased when input from the non-amblyopic eye was 
eliminated. Three things must be present to aIIow for normal processing and image 
f~~sion: image resoIution, image similarity and common directionality. Anisometropia 
and strabismus cause the images to be dissimilar quality or location in space, leading to 
an inability to assimiIatcJintcgrate the images, which disrupts sensory fusion, In order to 
stimulate clear f~~nctionnl vision in the arnblyopic eye, the visual input from the dorninan~ 
non-mblyopic eye must be blocked or penalized, so that the brain i s  forced lo utiIize tlze 
amblyopis eye, encouraging tile deveIop~nent of normal neural integration. The ultimate 
goal of amblyopia treatment is to improve the visual function of the arnblyopic eye, and, 
if possible, balance the visual input from both eyes setting thc stage for normal visual 
processing and sensory fusion. 
The Ideal AmbIyopia Treatment 
The perfect amblyopia treatment would be well tolerated by patients and their 
parents (who are ultimately responsible for following through with the treatment). It 
would be simple and effective, and achieve a maximal acuity in the shortest amount of 
time. For the parent, the perfect treatment would be both time and cost efficient. For the 
child, the perfect treatment would allow no interruption of current activities, be painless, 
and allow the child to maintain good cosmesis, or at least be undetectable by his peers. 
Additionally, the treatimnt must not have adverse effects, such as causing the vision 
development of the dominant eye to be sacrificed (reverse, or occlusion amblyopia), or 
increasing the frequency of strabismus due to disn~piion of unstabIe fusion. While 
occlusion therapy is a well-known option in the treatment of amblyopia, atropinc has also 
become an accepted and effective treatment option. 
Occlusion Therapy, the Gold Standard: 
The mainstay of amblyopia treatment has been and continues to be occlusion 
therapy. Occlusion treatment involves patching the non-amblyopic eye for a specified 
number of hours each day with an adhesive patch or spectacle mounted cloth patch. One 
of the major benefits of occlusion therapy is that it gives the doctor flexibility to 
customize the treatment according to the needs of each individual patient case (i.e. 
increasing or decreasing the number of  hour^).^ Another benefit is the fact that when the 
patient is wearing the occlusive patch the dominant eye is fully occluded thereby 
breaking the cycle of suppression that reinforces the amblyopia. This is especially helpful 
when treating constant strabismic amblyopes who often have binocular sensory 
adaptations in addition to amblyopia. 
While occlusion therapy has been shown to be an effective treatment there are 
significant drawbacks. Compliance with occlusion therapy is the major disadvantage of 
this mode of amblyopia treatment. It is very often a struggle to achieve an adequate level 
of compliance with patching, especially in young children. They often dislike wearing the 
eye patch for several reasons. First, forcing them to use their amblyopic eye causes them 
to have reduced visual acuity, at times drastically reduced, affecting their ability to 
function at school or at home. Second, the patch is cosmetically noticeable, causing them 
to stand out from their peers. School aged children are mindful of the social implications 
of being different then other children, so the social stigma of wearing the patch can cause 
resistance on the part of both the child and parent. Third, the adhesive patches may cause 
a skin irritation or problems with sweating during active play, especially in the 
summertime. Because of these problems with patching, patients are constantly inventing 
ways of removing andor peeking around the eye patch unless they are constantly 
supervised by an adult. With the increasing number of working mothers leading to 
multipIe care-providers, there is often much less p~en ta l  supervision than needed to 
maintain appropriate compliance.8 Ironically, the poorer the acuity, the more need for the 
treatment, but these are often the patients who most strongly resist treatment with 
patchi nge2 
Another disadvantage, not noted by children and not affecting compliance, yet 
quite impoftant, is that patching may disrupt binocularity in cases where this is not 
desirable, such as misometropic arnblyopes and intermittent strabismics. Wilh these 
patients it may be more beneficial to avoid total monocular occlusion as this may 
breakdown their fragiIe binocular system. For these patient types atropine therapy, 
which does not fully occlude the dominant eyc may be a more appropriate tl~erapy 
choice. 
Benefits and Drawbacks to Atropine therapy: 
Early in the twentieth century, Worth advocated monocular instillation of atropine 
as a treatment option for amblyopia.9 While some eyecare professionals have used 
atropine penalization to treat amblyopia it has not become a mainstream treatment choice. 
As demonstrated by the Pediatric Eye Disease Investigator Group (PEDIG) in Amblyopia 
Treatment Study 1 (ATS l), pharmaceutical penalization with atropine is a viable option 
for treating amblyopia. l o  Atropine therapy is accomplished by the instillation of 1 % 
atropine in the non-amblyopic eye, usually on a daily regimen. The resulting cycloplegia 
induces blur at near viewing distances in the dominant eye. This encourages the patient 
to use the amblyopic eye for near fixation, providing visual stimulation for a significant 
portion of each day. 
The success of any amblyopia treatment ultimately depends on compliance. With 
atropine there is potential for increased compliance due to several factors. First, there is 
less cosmetic effect with atropine, since anisocoria carries less social stigma than wearing 
a patch - especially in patients with dark irides. Second, there is also typically less 
emotional trauma with the instillation of drops compared to patching therapy. There is 
little to no stinging with atropine compared with many other drops because the pH 
balance is more isotonic with the cornea. It is easier to instill a drop that takes a few 
minutes then to force a child to wear a patch for hours. Third, with atropine penalization, 
there is no ability to peek around the pharmacologic "occlusion". Fourth, atropine 
treatment becomes a viable option for kids who develop skin sensitivity with the use of 
an adhesive eye patch. And fifth, with intermittent strabismic patients with fragile 
binocularity, atropine does not fully occlude, allowing some form of lower level 
binocularity to still exist thereby preventing an increase in the percentage of time 
strabismic. 
Adverse reactions to atropine use include mild ocular irritation and rare systemic 
reactions including flushing, irritability, fever, dry mouth, dry skin and tachycardia." 
However, these effects have rarely been reported during clinical trials. In the studies we 
researched, the rate of hypersensitivity ranged from 0.5% to 1.5% of the patients. I,IO,II 
The reactions may be minimized by instilling the drop at night or changing from drops to 
ointment. Another risk with any form of occlusion therapy is reverse amblyopia. This 
occurs when the visual acuity in the previously dominant eye decreases below the 
amblyopic eye. This occurs in a very small percentage of patients, but nevertheless can 
be reduced by using atropine on a part time basis. Only using the drops on weekends, for 
example, allows the effects of the drops to wear off late in the week so the patient is 
allowed a period where they are not penalized in the sound eye. Some have thought that 
a disadvantage to atropine is that the acuity improvement arrives at a slower pace than 
with occlusion therapy. While this may be the case, the PEDIG study ATS 1 in 2002 
showed that by the end of 6 months, the difference between success rates with the two 
treatments was statistically insignificant." 
Binocular benefits to atropine treatment: 
Simons, et a1 performed a retrospective study of 163 patients with strabismic 
amblyopia evaluating the monocular and binocular outcomes of three types of 
penalization. They compared optical penalization, traditional full time atropine usage 
and intermittent atropine (one to three times a week). One of the conclusions of the study 
was that each of the discussed treatment options can significantly improve mean 
binocularity. They remind us that pharmacologic and/or optical penalization allows each 
eye to be stimulated while still allowing the visual acuity to improve in the amblyopic 
eye. When an eye is penalized with atropine, the high-spatial frequencies are 
5,9,12 
compromised but the low spatial frequency signals are preserved. Since the high 
spatial frequencies of the dominant eye, containing detail information, are suppressed, the 
amblyopic eye can then develop adequate neural signals without competition from the 
already mature signals of the sound eye. At the same time, the low spatial frequency 
inputs to both eyes are left intact adequately preserving binocular v i ~ i o n . ~ , ~  
Patient profile for atropine usage 
When deciding whether atropine is appropriate, there are a few criteria which 
increase the success rate with this mode of treatment. The ideal patients are 
anisometropes and intermittent strabismics with amblyopia. Since direct occlusion has 
the potential to increase the frequency of strabismus in an intermittent strabismic patient, 
these patients are good atropine cases. Conversely, patients with steady eccentric fixation 
would not be good atropine candidates, since amblyopia treatment directed at penalizing 
the sound eye while allowing binocular viewing would only encourage this adverse 
adaptation pattern in the amblyopic eye. 
Another consideration for a good candidate would be acuity level in the 
amblyopic eye. The patient's acuity in the penalized eye should be at a level that allows 
fixation to switch to the amblyopic eye at near when the dominant eye is penalized. 
Most authors believe that when the amblyopic eye is at a level of 2011 00 or better, the 
dominant eye is blurred sufficiently to allow fixation to s ~ i t c h . ~  Therefore some 
practitioners that utilize atropine penalization have assumed that it would only be a viable 
option for patients with visual acuities in the amblyopic eye of 2011 00 or better. There 
were, however, patients in the Simons, et a1 study that had visual acuity in the amblyopic 
eye worse than 2011 00 and were successfully treated with atropine therapy.' These are 
important considerations when thinking about beginning a regimen of atropine 
penalization therapy. 
Combination therapy 
A third option to penalize the dominant eye is to optically penalize the eye at near. This 
can be done by blurring the sound eye with a fogging refracting lens, density filter, 
Bangerter foil, or plano lens. Placing the sound eye at a sufficient disadvantage can 
allow fixation to switch to the amblyopic eye. On a part-time, monitored basis, atropine 
treatment can be combined with optical penalization to further disadvantage the dominant 
eye in order to aid the patient in using their amblyopic One study looked at the 
effects of combining these forms of treatment with patients who had previously failed 
treatment with conventional occlusion therapy. Forty-two people were treated with 
combined optical and atropine treatment (COAT), with a hyperopic refraction of at least 
1.75 D in the sound eye. The patients had attempted occlusion for a mean of 36 weeks 
before commencing the study for anisometropic amblyopes, and 41 weeks for strabismic 
amblyopes. The mean number of hours occluded before study was 8 hours per week, 
only 9.5% of the prescribed amount. The mean entering visual acuity in amblyopic eye 
was 201150. The rate of improvement of visual acuity was six times faster than with 
occlusion alone. The success rate was 76%, when defined as at least doubling the VA in 
the amblyopic eye, and was 45% when defined as no interocular acuity difference. 
Twenty of the forty-two study patients had no further treatment after COAT, and 
maintained their VA at 93% of post treatment acuity.' 
Case reports 
Case #I 
Patient one is a 5 year old caucasian female who was referred to the Pediatric 
Strabismus Referral Center (PSRC) by a family friend (who is an O.D.) after the 
patient failed a pediatric eye screening. Her first eye exam was 2 weeks prior. 
Her ocular history was negative. Medical history was pertinent for a complicated 
pregnancy including induced labor due to maternal high blood pressure, liver 
failure, kidney failure and decreased amniotic fluid. Ocular alignment was ortho 
at both distance and near. Visual acuities were 20125 OD and 201200 0 s .  
Biomicroscopy revealed a grade 1 -2+ posterior subcapsular cataract in the left 
eye. Cycloplegic retinoscopy was +2.50 OD and +7.50 -0.50 X 180 0s. Visual 
acuity testing with a potential acuity meter was performed in the left eye both 
undilated and dilated and was found to be 201200. A spectacle prescription of 
plano sphere OD and +4.75 -0.75 X 1 80 OS was prescribed. An amblyopia 
treatment regimen of 6 hours per day of direct occlusion combined with 30 
minutes per day of home vision therapy was prescribed. Visual acuity improved 
to 20150 over a period of three months, but reached a plateau staying at the 20150 
to 20160 level. Patient regressed slightly following a bout of pneumonia to 20170 
with the whole Snellen chart, and improved with single letters to 20150. It was 
believed that this was the best acuity obtainable with the cataract. The patient 
underwent cataract extraction, and currently her full chart visual acuity is 20150. 
She is continuing her amblyopia therapy. 
Case #2 
Patient number two is a six year old caucasian female who was first seen in the 
primary care clinic of Pacific University. Ocular history was pertinent for a right 
eye turn, with history of patching and consideration of eye muscle surgery. She 
had lost her glasses and had not worn them for some time prior to our exam. The 
medical history was pertinent for maternal narcotic drug use during pregnancy. 
She presented with a constant large angle right exotropia with right hypotropia. 
Glasses were prescribed with powers of +6.25 -1.00 170 right eye and +4.75 
sphere left eye, giving acuity of 201100 and 20125 respectively. She was then 
referred to the PSRC where the strabismus was quantified as a constant 35 prism 
diopter right exotropia. On fwther evaluation she showed a minus three 
restriction of the right inferior oblique with 1 + over-action of the left superior 
rectus indicating a possible Brown's Syndrome. At this visit her distance visual 
acuity in the right eye was 20160 with single letters, while the left eye maintained 
visual acuity of 20130 with the full chart. She showed no stereopsis with either 
Lang or randot targets with superimposed 35 prism diopters of neutralizing prism. 
Patching four hours per day combined with active vision therapy for 45 minutes 
each day was prescribed at this appointment. After 2 months of patching therapy 
the patient's single letter Snellen acuity improved to the 20140 to 20150 range. 
Due to compliance issues with patching the patient was started on atropine 
therapy with 45 minutes of vision therapy per day. Following two months of 
atropine treatment her distance Snellen acuity in the right eye improved to 20140 
with the full chart and a near acuity of 20160. The left eye was 20125 with a near 
acuity of 201120. Six months later the patient underwent strabismus surgery 
reducing her deviation to a 6 prism diopter right exotropia at distance and a 10 
prism diopter right exotropia combined with a 3 prism diopter right hypertropia at 
near. Following surgery the patient was able to achieve 100 arc seconds of 
stereopsis with wirt circles. Her final VA had regressed slightly to 20150 whole 
chart snellen acuity. (Note: Patient had a very unstable home environment, not 
conducive to compliance.) 
Case #3 
Patient three is an eight year old caucasian female who was referred to Pacific 
University's Pediatric Strabismus Referral Center (PSRC) by her optometrist for 
treatment of esotropia and amblyopia in her left eye. Parents were interested in 
strabismus surgery. Ocular history was positive for an eye turn that was 
diagnosed at age 5 when she received glasses and had limited success with 
patching treatment. Her medical history was positive for attention deficit disorder 
for which the patient has taken adder01 as needed. She presented with a constant 
9 prism diopter left esotropia at distance and an intermittent 6 prism diopter 
esotropia at near. Her referring O.D. wanted to initiate patching therapy but the 
patient refused to wear the patch. Her habitual glasses Rx was found to be +4.50 - 
1.00 X 180 OD and +5.75 -1.50 X 180 OS witha+1.75 Add OU, giving her 
distance acuity of 20130 OD 201200 OS and near acuity of 20130 OD and 20180 
0 s .  Atropine penalization of the right eye was begun at this visit. At her three 
week follow up appointment her distance acuity in the left eye improved to 20170 
using the whole Snellen chart. After poor compliance with her active home vision 
therapy her visual acuity reached a plateau at the 20170 level and did not improve 
over the next 6 months. Atropine therapy was discontinued at this time. Over the 
next six months the patient was treated with patching and home vision therapy 
with weekly therapy sessions. Her vision remained at the 20170 to 20160 level 
over this time period. At her appointment six months after discontinuing atropine 
therapy she exhibited 3 prism diopters of nasal eccentric fixation in the left eye, 
which would give a predicted visual acuity of 20180. Because of continual 
compliance issues no active therapy to develop central fixation was started for this 
patient at this time. 
Case #4 
Patient four is a seven year old caucasian female who presented to the PSRC 
clinic of Pacific University with a chief complaint of the "right eye not seeing as 
well as the left". Problem was noted at the pediatricians and she had a complete 
vision exam several weeks prior to our evaluation. The patient's eye health 
history was unremarkable. Her family ocular history was positive for strabismus 
on her father's side. Cover testing without correction revealed a 12 prism diopter 
left esotropia at near and a 6-8 prism diopter left esotropia at distance. Her initial 
uncorrected distance visual acuity was 20120 OD and 51200 0s. Dry retinoscopy 
showed a glasses prescription of +1 .OO DS OD and +7.00 - 1.50 X 175 0 s .  Wet 
retinoscopy was +2.50 -0.25 X 170 OD 20120 and +8.25 -2.00 X 175 with no 
improvement 0s. A glasses prescription was written for the dry retinoscopy 
value and direct patching was initiated at 6 hours per day with near activities. At 
the one month follow-up appointment cover testing with correction showed a 4 
prism diopter left esotropia at distance and a 10 prism diopter left esotropia at 
near. Visuoscopy showed 1-2 prism diopters of unsteady nasal eccentric fixation. 
Distance visual acuity in the left eye improved to 201160 with BVAT. After three 
months of this direct patching regimen the patient's percentage of time strabismic 
decreased. During the five months after initiating patching therapy the patient 
improved and plateaued at a 20180 level in the left eye. Atropine therapy was 
begun with one drop every morning in the right eye, combined with one hour of 
daily vision therapy. Over the next two weeks her distance visual acuity 
improved to 20160 and remained plateaued at that level for the next five months. 
Summary of case studies 
All cases benefited both in improvement in visual functioning, and in compliance with 
the "penalization" portion of the therapy. It is still a challenge to engage some of these 
young patients in the active home therapy techniques that appear important in hastening 
visual function improvement. While the above patients did not reach a final acuity level 
of 20120 OU, each had unique challenges that limited the final potential visual acuity. 
Case one had improved to the limits of her cataract, and continues to improve now that it 
has been removed. Case two improved 50%. Case three improved to approximately 
three times better acuity, even with eccentric fixation and a compliance problem that did 
not permit home therapy. Case four improved from 201800 equivalent to 2011 60, 
approximately four times better acuity. 
Cost Comparison 
Studies, which compare the cost to the patient of using atropine or patcliing as a 
treatment option, indicate that cost is a mute point. In 2002, the Pediatric Eye Disease 
Investigator Crroup (PEDIG) found that assuming the cost of a patch to be approximately 
$0.35 and the cost of a 15ml bottle of atropine to be $1 0, patching for six months would 
cost about $1 00 end using drops daily for six months would cost $1 0." Adding in the 
cost of possible lens cl~anges lo optically penalize the atropinized eye, this stilt makes 
atropine a slightly more economical option. However, one editorial indicated that if h c  
patient needed to continue one more visit past six ~nonths, they become approximately 
equal. ' 
Amblvopia Treatment Studies 
PEDIG has developed a series of studies that test the relative effectiveness of currently 
used amblyopia treatments. The Amblyopia Treatment Study 1 (ATS 1) found that both 
patching and atropine therapies were effective treatments for moderate amblyopia in 
children 3-7 years old. It was found in ATS 1 that the six-month acuity had improved 
from baseline by 3 or more lines in 79% of the subjects in the patched group and 74% for 
the atropine group. "In summary, both atropine and patching are effective treatments for 
moderate amblyopia (in the tested age group)." Patching showed a slightly more rapid 
improvement than atropine. Perhaps if they had used optical penalization therapy for the 
hyperopes earlier in the study, the two methods would have been closer in treatment 
duration. l o  Atropine does, however, have the advantage of ease of administration, better 
cosmesis and compliance better during treatment. In ATS 1 the researchers administered 
one drop of atropine everyday. Since the cycloplegia effect lasts much longer than one 
day, studies are attempting to further define the minimum application time for atropine to 
obtain maximum effect. 
Conclusion: 
While many options exist, the majority of eye care practitioners historically have 
treated amblyopia with some form of occlusion therapy. In an unpublished study in 
1997, practicing pediatric ophthalmologists were surveyed as to what treatment they used 
for amblyopia treatment. Ninety seven percent reported using occlusion therapy as their 
initial treatment.'' Several studies have indicated that atropine penalization is an effective 
primary treatment for mild to moderate levels of strabismic amblyopia. Simons, et a1 
point out that atropine is not simply a fall back method for "use with occlusion failures or 
for post-occlusion acuity maintenan~e."~ Due to this evidence and other recent studies, 
the decision of which penalization method to use can now depend primarily on what is 
practical for a given patient.5 
Patching offers a safe, non-pharmaceutical, complete occlusion, which allows the 
doctor the flexibility to alter the treatment dose depending on the patient profile. Part- 
time, full-time, or alternating occlusion can be easily maintained with a patch that begins 
effectivity upon placement, and ends effectivity when removed. Patients who would 
benefit from patching would be those who have acuity in the amblyopic eye less than 
2011 00. Those who are constant strabismics will benefit from patching by breaking down 
any pattern of suppression and allowing the amblyopic eye to fully develop. 
Atropine penalization offers the doctor and patient another treatment 
option with equal efficacy, but also several benefits. Most importantly, there is a 
potential for increased compliance. For anisometropic amblyopes and amblyopic patients 
whose constant strabismus is now intermittent, atropine maintains a protective level of 
binocularity as opposed to full occlusion with patching. Atropine can therefore prevent an 
increase in strabismus in a patient with a fragile binocular system. Atropine therapy also 
offers less emotional trauma and familial strife to persistent children who continually 
refuse to wear the patch. Atropine does not irritate the skin, nor require constant parental 
supervision to assure compliance. In active children, atropine will not "come off' as 
patches do when the skin becomes warm. All of these subtle differences lead to an 
increased compliance rate for many patients. While both options can be used in most 
cases, knowing that the outcomes are statistically equal allows us to tailor our treatment 
method and duration to assure the best compliance. This increased compliance provides 
the most rapid improvement in visual acuity, as well as providing optimal patient and 
parent satisfaction. 
Current ongoing studies by PEDIG will examine other aspects of atropine 
penalization such as intermittent use. There is a study comparing weekend only versus 
daily atropine instillation to determine the duration of efficacy as well as to assess the 
effects of allowing the patients to have some time to use binocular vision while the 
previous drops are no longer effective. Another current study assesses amblyopia 
treatment in children older than 7 years of age. There are always new studies that will 
allow us to further understand amblyopia. It is important to constantly look for recent 
evidence of effective patient management, and be amenable to altering the treatment 
plans according to current information and evidence. Atropine offers equal results with 
improved patient and parent satisfaction and fewer confrontations ultimately leading to 
better compliance. This is clinically quite powerful. 
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